Top Markets
Coin of the day
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Rang in Aktien #20442
Fusion Antibodies plc, a contract research organization, engages in the... Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
Aktienkurs
$0.16328419
Marktkapitalisierung
$204.14K
Veränderung (1 Tag)
4.35%
Veränderung (1 Jahr)
102.45%
Land
GB
Handel Fusion Antibodies plc (FAB)

Kategorie

P/S-Verhältnis für Fusion Antibodies plc (FAB)
P/S-Verhältnis zum March 2026 TTM: 9.79
Laut den neuesten Finanzberichten und dem Aktienkurs von Fusion Antibodies plc beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 9.79. Am Ende des Jahres 2024 lag das P/S-Verhältnis bei 1.88.
P/S-Verlauf für Fusion Antibodies plc von 2013 bis 2026
P/S-Verhältnis zum Jahresende
Jahr P/S-Verhältnis ändert
2026 (TTM) 9.79 226.39%
2025 3.00 59.38%
2024 1.88 -45.47%
2023 3.45 6.43%
2022 3.24 -66.20%
2021 9.60 78.11%
2020 5.39 86.72%
2019 2.89 -54.34%
2018 6.32 -55.67%
2017 14.25 -22.61%
2016 18.42 -38.61%
2015 30.00 -20.48%
2014 37.73 -43.99%
2013 67.37 0.00%
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/S-Verhältnis P/S-Verhältnis-Differenz Land
3.55 -63.73%
DK
9.90 1.13%
US
5.40 -44.83%
US
6.14 -37.31%
BE
12.90 31.71%
NL